FDA Authorizes COVID-19 Test to Identify Specific SARS-CoV-2 Lineages

Labcorp VirSeq SARS-CoV-2 NGS Test is for the identification and differentiation of SARS-CoV-2 PANGO lineages

If your email program has trouble displaying this email, view as a webpage. FDA Authorizes First COVID-19 Test to Identify Specific SARS-CoV-2 Lineages The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the Laboratory Corporation of America (Labcorp) VirSeq SARS-CoV-2 NGS Test on the PacBio Sequel II sequencing system.  The SARS-CoV-2 virus has mutated over time resulting in genetic variation in circulating virus strains, also called lineages. The Labcorp VirSeq SARS-CoV-2 NGS Test is: The first COVID-19 test authorized for the identification and differentiation of SARS-CoV-2 Phylogenetic Assignment of Named Global Outbreak (PANGO) lineages. A next-generation sequencing (NGS) based test authorized for testing patient respiratory samples (such as anterior nasal or nasopharyngeal swab samples) identified as SARS-CoV-2 positive using Labcorp's COVID-19 RT-PCR Test and Labcorp SARS-CoV-2 & Influenza A/B Assay. Intended to be used when a health care provider decides, based on a patient's medical history and other diagnostic information, that the test results may help in deciding the appropriate clinical care for the patient. The test can be performed at certain laboratories designated by Labcorp that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) that meet the requirements to perform high-complexity testing. Read More Questions? If you have questions about this EUA announcement, contact the Division of Industry and Consumer Education.

Follow us on Twitter at @FDADeviceInfo Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA